Project description
Innovative tools for structural analysis of biotherapeutics
Advances in biotherapeutics-based treatments for human diseases including COVID-19 are crucial. Mass spectrometry (MS) is a powerful technique for supporting the development of biotherapeutics-based drugs and clinical diagnosis. However, even versatile high-performance Orbitrap Fourier transform mass spectrometry (FTMS) may show limitations in the structural analysis of complex biotherapeutics, such as monoclonal antibodies and antibody-drug conjugates. The EU-funded A2MStools project identified the absence of hardware and software tools needed to acquire and analyse the unreduced time-domain data as the restricting factor in biotherapeutics structure analysis. The project will investigate the added value of an access to the existing but currently unavailable unreduced time-domain data for the Orbitrap FTMS platforms and allied software tools to handle these (big) data sets.
Objective
Biotherapeutics, such as monoclonal antibodies (mAbs) and antibody-drug conjugates (ADCs), constitute an increasingly important class of molecular drugs. Accelerating our society’s access to novel biotherapeutics-based therapies and diagnostic tests for existing and new clinical indications, including those caused by COVID-19, is critical. The exceptional specificity and selectivity of mass spectrometry (MS) renders this analytical technique a powerful tool in development of biotherapeutics-based drugs and clinical diagnostics. Nevertheless, even Orbitrap Fourier transform mass spectrometry (FTMS), which dominates the high-performance MS field, may demonstrate limited performance in structural analysis of the very complex mAbs and ADCs. Indeed, while the user-accessible Orbitrap data (processed mass spectra with reduced information) may be of a sufficient quality and information content for small molecule and isolated proteins analysis, it is not for the complex biotherapeutics. We identified the limiting factor that inhibits biotherapeutics structure analysis being the absence of hardware and software tools to acquire (access and provide to the end-users) and analyze the un-reduced data (e.g. time-domain signals or transients). With these tools in hands, the end-users would be able to increase performance and productivity of their biopharma workflows on the Orbitraps (e.g. leading to increased sensitivity and resolution, and thus leading to faster identification of more species and their deeper sequencing), as well as create novel workflows, not possible otherwise. The A2MStools (access & analysis MS tools) aims to address this limitation by: (i) providing access to the currently unavailable un-reduced data (transients) for the Orbitraps FTMS platforms with enabled BioPharma capabilities, and (ii) empowering analytical scientists with the data analysis tools capable of handling the datasets of unprocessed data in the most comprehensive and innovative ways.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques. See: The European Science Vocabulary.
- natural sciences computer and information sciences data science
- natural sciences computer and information sciences software
- natural sciences biological sciences biochemistry biomolecules proteins
- medical and health sciences health sciences infectious diseases RNA viruses coronaviruses
- natural sciences chemical sciences analytical chemistry mass spectrometry
You need to log in or register to use this function
We are sorry... an unexpected error occurred during execution.
You need to be authenticated. Your session might have expired.
Thank you for your feedback. You will soon receive an email to confirm the submission. If you have selected to be notified about the reporting status, you will also be contacted when the reporting status will change.
Programme(s)
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
Multi-annual funding programmes that define the EU’s priorities for research and innovation.
-
H2020-EU.1.2. - EXCELLENT SCIENCE - Future and Emerging Technologies (FET)
MAIN PROGRAMME
See all projects funded under this programme -
H2020-EU.1.2.1. - FET Open
See all projects funded under this programme
Topic(s)
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Calls for proposals are divided into topics. A topic defines a specific subject or area for which applicants can submit proposals. The description of a topic comprises its specific scope and the expected impact of the funded project.
Funding Scheme
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
Funding scheme (or “Type of Action”) inside a programme with common features. It specifies: the scope of what is funded; the reimbursement rate; specific evaluation criteria to qualify for funding; and the use of simplified forms of costs like lump sums.
CSA-LSP - Coordination and support action Lump sum
See all projects funded under this funding scheme
Call for proposal
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
Procedure for inviting applicants to submit project proposals, with the aim of receiving EU funding.
(opens in new window) H2020-FETOPEN-2018-2020
See all projects funded under this callCoordinator
Net EU financial contribution. The sum of money that the participant receives, deducted by the EU contribution to its linked third party. It considers the distribution of the EU financial contribution between direct beneficiaries of the project and other types of participants, like third-party participants.
1015 Lausanne
Switzerland
The organization defined itself as SME (small and medium-sized enterprise) at the time the Grant Agreement was signed.
The total costs incurred by this organisation to participate in the project, including direct and indirect costs. This amount is a subset of the overall project budget.